US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Beactica conducts first advisory meeting with the Swedish Medical Products Agency regarding the development of BEA-17

Beactica Therapeutics AB, the Swedish precision medicine company, today announced that it has conducted a first scientific advisory meeting with the Swedish Medical Products Agency regarding the drug candidate BEA-17. Specifically, the company's plans for the preclinical development aimed at enabling dosing of BEA-17 in humans were discussed. The Swedish Medical Products Agency expressed its support for Beactica's plans. Positive discussions were also held regarding the design and setup of a first clinical trial with BEA-17. "It is an important milestone for BEA-17 and Beactica to have

Beactica Therapeutics strengthens its preclinical development team

Beactica Therapeutics AB, the Swedish precision oncology company, today announced two appointments to its preclinical development team. Dr Anneli Hällgren will lead the preclinical development and Dr Carl Magnus Andersson will lead the CMC activities. The appointments are made in preparation for IND-enabling studies of preclinical candidate BEA‑17, a novel small molecule cancer immunotherapeutic agent under development by Beactica.Dr Anneli Hällgren has more than 25 years of experience from drug development within several therapeutic areas and with emphasis on preclinical development

Beactica Therapeutics receives FDA Orphan Drug Designation for BEA-17 for the treatment of glioblastoma

PRESS RELEASE Uppsala, Sweden – 1 February 2023   Beactica Therapeutics AB, the Swedish precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BEA-17 for the treatment of glioblastoma (GBM). BEA-17 is a first-in-class small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. Overexpression of LSD1 has been implicated in the pathogenesis of a variety of cancers, including GBM. There are currently no approved therapies for GBM that target this enzyme. “The FDA’s decision

Dong-A ST and Beactica Therapeutics mutually agree to conclude oncology collaboration

Dong-A ST Co., Ltd. (170900: Korea SE), a Korean pharmaceutical company, and Beactica Therapeutics AB, a Swedish precision oncology company, today announced that they have mutually agreed to terminate their collaboration and licensing agreement. The collaboration focused on developing novel candidate compounds against multiple cancer targets of mutual interest. The partnership has been productive, and multiple compound classes are now in various stages of lead generation and optimization.  As part of the termination, both Dong-A ST and Beactica Therapeutics will gain exclusive global

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe